Related Experiment Video
Updated: Jun 23, 2026
Body Composition and Metabolic Caging Analysis in High Fat Fed Mice
Published on: May 24, 2018
Preclinical efficacy of engineered CircRNA-GDF15@LNP for sustained weight loss and metabolic regulation in
Abstract:
Obesity as a global epidemic demands effective therapies, with three core management goals: appetite suppression, metabolic acceleration, and weight rebound prevention. Unfortunately, current obesity treatments often fail to simultaneously achieve these goals, and some may cause adverse effects or poor long-term efficacy, thereby complicating the clinical management process. Herein, a novel long-acting circular RNA (CircRNA) based formulation (CircGDF15@LNP) is designed for precise obesity control and metabolic improvement. This delivery system was optimized from established lipid nanoparticle (LNP) formulations, and combines structurally optimized CircRNA encoding mutant growth differentiation factor 15 (GDF15), taking advantage of the high stability and long-lasting expression of CircRNA for efficient GDF15 protein replacement therapy. After biweekly intravenous injection into diet-induced obesity (DIO) mice for 4 weeks, CircGDF15@LNP exhibits prolonged GDF15 overexpression and stable RNA persistence in vitro and in vivo, subsequently activating PPARα/γ signaling and UCP1 expression in liver and adipose tissue to regulate lipid metabolism and adaptive thermogenesis. This study presents a versatile CircRNA-based GDF15 protein replacement therapy for metabolic disorder therapy and provides an innovative approach for addressing obesity and related metabolic complications.
Insights
A new circular RNA (CircRNA) therapy using lipid nanoparticles (LNPs) effectively controls obesity by boosting GDF15 protein levels. This approach improves metabolism and thermogenesis, offering a promising treatment for obesity and related disorders.
Area of Science:
- Biotechnology
- Molecular Biology
- Metabolic Disorders
Background:
- Obesity is a global epidemic requiring treatments that suppress appetite, accelerate metabolism, and prevent weight regain.
- Current obesity therapies often lack efficacy, have adverse effects, or fail to meet all management goals.
Purpose of the Study:
- To develop a novel, long-acting circular RNA (CircRNA) formulation for precise obesity control and metabolic improvement.
- To create an efficient GDF15 protein replacement therapy using a stable CircRNA-based delivery system.
Main Methods:
- A lipid nanoparticle (LNP) formulation (CircGDF15@LNP) was developed using structurally optimized CircRNA encoding mutant growth differentiation factor 15 (GDF15).
- The formulation was administered via biweekly intravenous injections to diet-induced obesity (DIO) mice for four weeks.
- In vitro and in vivo assessments were performed to evaluate RNA persistence and GDF15 overexpression.
Main Results:
- CircGDF15@LNP demonstrated prolonged GDF15 overexpression and stable RNA persistence.
- The treatment activated PPARα/γ signaling and UCP1 expression in liver and adipose tissues.
- Key metabolic pathways regulating lipid metabolism and adaptive thermogenesis were modulated.
Conclusions:
- CircRNA-based GDF15 protein replacement therapy offers a versatile approach for metabolic disorder treatment.
- CircGDF15@LNP presents an innovative strategy for managing obesity and associated metabolic complications.
